TIKOMED’S ILB ® resolves inflammatory scarring and promotes functional tissue repair in data published in npj Regenerative Medicine
Viken – 7[ ]January 2021 – A new study on TIKOMED’s lead drug candidate, ILB[®], was published in npj Regenerative Medicine today. The peer-reviewed data from rodent and human disease models showed that ILB[® ]leads to tissue remodelling, reduced fibrosis and functional tissue regeneration – observations indicating the potential of ILB[®] to alleviate fibrotic diseases. Professor Ann Logan, from the University of Warwick, leader of the research team and senior author of the publication, said, “Inflammation plays a vital role in healing, but when it becomes uncontrolled the immune system